Down-regulation of vascular endothelial growth factor expression by anti-Her2/neu single chain antibodies.
HER-2/neu is overexpressed in 25-30% of breast tumors. Signaling through HER-2/neu leads to an increase in the production of vascular endothelial growth factor (VEGF) and enhances angiogenesis. We evaluated the effects of three specific anti-HER2/neu single chain-Fv (scFv) antibodies on the expression level of VEGF in HER2/neu-expressing breast cancer cell lines. A nonimmunized human scFv library was panned against three epitopes of HER2/neu. BT-474 human breast cancer cell line was treated with three specific anti-HER2/neu scFv antibodies and the amount of VEGF gene transcript was determined by quantitative real-time PCR. The expression of VEGF protein was analyzed by western blot. All three scFv antibodies along with their combination inhibited VEGF expression at both the gene and protein levels. Our results show that anti-HER2/neu recombinant antibodies can be considered as anti-angiogenic agents in HER2/neu-positive breast cancers.
Recombinant Antibody Laboratory, Department of Immunology, Graduate School for Advanced Biomedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Foroogh
F
Nejatollahi
Mahdi
M
Asgharpour
Mansooreh
M
Jaberipour
D000970:Antineoplastic Agents / Q000494:pharmacology*; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000378:metabolism*; D045744:Cell Line, Tumor; D015536:Down-Regulation; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D060888:Real-Time Polymerase Chain Reaction; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D057127:Single-Chain Antibodies / Q000494:pharmacology*; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis*
D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D057127:Single-Chain Antibodies; D042461:Vascular Endothelial Growth Factor A
Curr Pharm Biotechnol. 2000 Nov;1(3):253-63
11469383
Cancer Res. 2005 Jan 15;65(2):650-6
15695410
N Engl J Med. 1991 Jan 3;324(1):1-8
1701519
Med Oncol. 2011 Dec;28 Suppl 1:S80-90
20967512
Nature. 2005 Sep 22;437(7058):497-504
16177780
Ann Oncol. 2010 May;21(5):955-60
19940005
Semin Oncol. 1999 Aug;26(4 Suppl 12):51-9
10482194
Crit Rev Oncol Hematol. 2012 Dec;84 Suppl 1:e79-85
20817545
J Clin Oncol. 2002 Feb 1;20(3):719-26
11821453
Oncogene. 2000 Jul 20;19(31):3460-9
10918604
Br J Cancer. 2001 Jul 20;85(2):273-8
11461089
Am J Pathol. 1997 Dec;151(6):1523-30
9403702
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
Mol Biol Cell. 2002 Nov;13(11):4029-44
12429844
Oncologist. 2000;5 Suppl 1:37-44
10804090
Am J Physiol Cell Physiol. 2001 Jun;280(6):C1375-86
11350732
Cancer Res. 2001 Jul 15;61(14):5407-14
11454684
J Clin Oncol. 2004 May 1;22(9):1621-9
15117984
Mayo Clin Womens Healthsource. 2007 Jun;11(6):3
17476181
Semin Oncol. 2002 Jun;29(3 Suppl 11):29-37
12138395
Int J Cancer. 1990 Mar 15;45(3):457-61
1968437
Semin Oncol. 2003 Oct;30(5 Suppl 16):38-48
14613025
FEMS Immunol Med Microbiol. 2002 Nov 15;34(3):237-44
12423777
Handb Exp Pharmacol. 2008;(181):183-219
18071947
Prog Cardiovasc Dis. 2010 Sep-Oct;53(2):94-104
20728696
Drugs. 2007;67(12):1793-9
17683175
J Biol Chem. 1996 Jan 12;271(2):603-6
8557658
Biochem Biophys Res Commun. 2005 Jan 14;326(2):455-65
15582599
Histol Histopathol. 2005 Jul;20(3):1005-15
15944951
Curr Opin Biotechnol. 2002 Dec;13(6):603-8
12482521
Biochem Biophys Res Commun. 1999 Nov 2;264(3):781-8
10544009
Cell. 1996 Dec 27;87(7):1153-5
8980221
Cancer Chemother Pharmacol. 2004 Feb;53(2):186-90
14605867
Clin Cancer Res. 2004 Mar 1;10(5):1706-16
15014023
Oncogene. 2000 Dec 11;19(53):6102-14
11156523
Am J Physiol Cell Physiol. 2001 Jun;280(6):C1358-66
11350730
Exp Cell Res. 1999 Mar 15;247(2):495-504
10066377
Cancer Treat Rev. 2009 Apr;35(2):121-36
19008049
Cancer Metastasis Rev. 1996 Jun;15(2):213-9
8842493
Acta Oncol. 2009;48(7):964-70
19734999
Oncogene. 2006 Nov 2;25(52):6986-96
16715132
Eur J Cancer. 2004 Jan;40(1):33-42
14687787
Oncogene. 2002 Jan 10;21(2):328
11840330